Last Updated on October 15, 2024 by The Health Master
USFDA issued EIR
Torrent Pharmaceuticals, a leading pharmaceutical company, announced that the USFDA issued EIR.
The United States Food and Drug Administration (USFDA) has issued an encouraging Establishment Inspection Report (EIR) for the company’s manufacturing facility located in Dahej, Gujarat.
This development signifies a significant step towards improved operations and growth prospects for Torrent Pharmaceuticals.
Successful Closure of the Inspection:
Following the issuance of the EIR by the USFDA, Torrent Pharmaceuticals confirmed the successful closure of the inspection.
This achievement underscores the company’s commitment to maintaining high manufacturing standards and regulatory compliance.
The closure of the inspection holds substantial implications for Torrent Pharmaceuticals’ future endeavors.
Progress from the Previous Setback:
In a notable turnaround, the Dahej facility faced regulatory challenges in March 2019 when it was placed under Official Action Indicated (OAI) status by the USFDA.
However, Torrent Pharmaceuticals diligently addressed the concerns and worked towards rectifying the issues.
Re-inspection and Observations:
The USFDA conducted a re-inspection of the Dahej facility in May of the current year, spanning from May 17 to May 25.
Following this re-inspection, the regulatory body issued a Form 483 outlining two observations related to the facility’s operations.
As part of their dedication to quality and compliance, the company took meticulous steps to address these observations.
Upgraded Site Classification:
As a positive outcome of the re-inspection process and subsequent efforts, the site’s classification has been upgraded to Voluntary Action Indicated (VAI).
This upgraded status is indicative of the strides made by Torrent Pharmaceuticals in resolving the previously highlighted concerns.
The new classification holds promising implications for the company’s future endeavors in the United States pharmaceutical market.
Impetus for Growth and Product Offerings:
The improved classification of the Dahej facility augments Torrent Pharmaceuticals’ growth prospects in the highly competitive US pharmaceutical market.
This positive development opens doors for the company to introduce new and innovative product offerings, thereby expanding its market presence and catering to diverse healthcare needs.
Manufacturing Spectrum:
The Dahej facility specializes in the production of Active Pharmaceutical Ingredients (APIs) and formulations, catering to Torrent Pharma’s international markets.
The facility’s global reach underscores its significance as a key contributor to the company’s operations and growth trajectory.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
Procedural lapses flagged at Aurobindo Pharma by USFDA: Telangana
USFDA completes PADE inspection at Marksans with 2 observations
USFDA concludes inspection at Granules Pharma with zero observations
USFDA concludes inspection at Gland Pharma with zero observation
USFDA Warning Letter resolved: Lupin, Goa, Pithampur
USFDA concludes inspection at Eugia Pharma with zero observation
Understanding GMP, cGMP, and WHO-GMP
Quality Assurance in the Pharmaceutical Industry
Duties and responsibilities of QA person in Pharma Industry
Difference: Disintegration and Dissolution test in pharma industry
Understanding DQ, IQ, PQ, and OQ in the Pharma Industry
USFDA issues Form 483 with 2 observations to Gland Pharma: Hyderabad
Pharmacy Practice Regulations 2015 implemented: Mizoram
Recommendations for expediting TMR for Medical Devices
USFDA gives approval for Guaifenesin ER Tablets
Key Requirements for RTI Orders: High Court’s Directives
Gujarat FDCA: M-Governance soon for Drug Manufacturers and Medical Stores
Glenmark fined $30 million to resolve drug price-fixing charges
Drug recall: Alembic, Aurobindo recall these drugs for this reason
National Policy ready for R&D in Pharma-Medical Device Industry
India launches Rs 5,000 Crore R&D Incentive Scheme for Pharma Industry
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
